SK 12
Alternative Names: SK-12Latest Information Update: 28 Aug 2026
At a glance
- Originator Zhiyi Biotechnology
- Class Bacteria
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Unspecified in China (PO, Tablet)
- 11 Jul 2022 Preclinical trials in Unspecified in China (PO) (Zhiyi Biotechnology pipeline, July 2022)